

Peter Valent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/965483/publications.pdf>

Version: 2024-02-01

748
papers

44,207
citations

1992

101
h-index

4116

175
g-index

769
all docs

769
docs citations

769
times ranked

31064
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 2454-2465.	1.4	2,458
2	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. <i>Nature</i> , 2011, 478, 524-528.	27.8	1,656
3	Diagnostic criteria and classification of mastocytosis: a consensus proposal. <i>Leukemia Research</i> , 2001, 25, 603-625.	0.8	1,020
4	New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. <i>Blood</i> , 2007, 110, 4385-4395.	1.4	719
5	Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 607-612.e9.	2.9	604
6	Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. <i>Blood</i> , 2007, 110, 4055-4063.	1.4	600
7	Cancer stem cell definitions and terminology: the devil is in the details. <i>Nature Reviews Cancer</i> , 2012, 12, 767-775.	28.4	599
8	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. <i>Journal of Clinical Oncology</i> , 2012, 30, 820-829.	1.6	584
9	Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. <i>Blood</i> , 2017, 129, 1420-1427.	1.4	520
10	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 215-225.	2.1	513
11	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. <i>Leukemia Research</i> , 2007, 31, 727-736.	0.8	478
12	Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. <i>Nature</i> , 2015, 525, 543-547.	27.8	414
13	Mast Cells, Mastocytosis, and Related Disorders. <i>New England Journal of Medicine</i> , 2015, 373, 163-172.	27.0	402
14	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016, 374, 2530-2541.	27.0	383
15	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	30.7	372
16	Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1194-1199.	2.4	340
17	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 35-45.	2.9	289
18	BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1 α , through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. <i>Blood</i> , 2002, 100, 3767-3775.	1.4	275

#	ARTICLE	IF	CITATIONS
19	The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13283-13288.	7.1	274
20	Mast cell activation syndrome: Proposed diagnostic criteria. Journal of Allergy and Clinical Immunology, 2010, 126, 1099-1104.e4.	2.9	266
21	Anemia at older age: etiologies, clinical implications, and management. Blood, 2018, 131, 505-514.	1.4	266
22	Identification of common allergenic structures in hazel pollen and hazelnuts: A possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen. Journal of Allergy and Clinical Immunology, 1992, 90, 927-936.	2.9	265
23	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
24	Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. American Journal of Hematology, 2011, 86, 533-539.	4.1	254
25	Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine. Journal of Innate Immunity, 2016, 8, 111-120.	3.8	249
26	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017, 18, 2162-2174.	6.4	244
27	Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors. New England Journal of Medicine, 1994, 331, 1116-1121.	27.0	243
28	Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 2015, 125, 901-906.	1.4	239
29	PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood, 2006, 107, 752-759.	1.4	235
30	Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood, 2005, 105, 3303-3311.	1.4	226
31	Diagnostic Value of Immunostaining for Tryptase in Patients With Mastocytosis. American Journal of Surgical Pathology, 1998, 22, 1132-1140.	3.7	225
32	Recombinant Carp Parvalbumin, the Major Cross-Reactive Fish Allergen: A Tool for Diagnosis and Therapy of Fish Allergy. Journal of Immunology, 2002, 168, 4576-4584.	0.8	223
33	Comprehensive mutational profiling in advanced systemic mastocytosis. Blood, 2013, 122, 2460-2466.	1.4	222
34	The Basophil-Specific Ectoenzyme E-NPP3 (CD203c) as a Marker for Cell Activation and Allergy Diagnosis. International Archives of Allergy and Immunology, 2004, 133, 317-329.	2.1	218
35	Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leukemia Research, 2003, 27, 635-641.	0.8	217
36	Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell, 2005, 7, 87-99.	16.8	213

#	ARTICLE	IF	CITATIONS
37	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	2.2	213
38	Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. <i>Leukemia Research</i> , 2001, 25, 543-551.	0.8	211
39	Mastocytosis: State of the Art. <i>Pathobiology</i> , 2007, 74, 121-132.	3.8	210
40	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.9	210
41	Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. <i>Leukemia Research</i> , 2001, 25, 529-536.	0.8	206
42	Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. <i>Blood</i> , 2014, 123, 3951-3962.	1.4	189
43	Diagnosis and treatment of systemic mastocytosis: state of the art. <i>British Journal of Haematology</i> , 2003, 122, 695-717.	2.5	187
44	Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease. <i>International Archives of Allergy and Immunology</i> , 2002, 128, 136-141.	2.1	184
45	Cell Surface Structures on Human Basophils and Mast Cells: Biochemical and Functional Characterization. <i>Advances in Immunology</i> , 1992, 52, 333-423.	2.2	181
46	Mastocytosis: Pathology, genetics, and current options for therapy. <i>Leukemia and Lymphoma</i> , 2005, 46, 35-48.	1.3	180
47	Identification of Der p 23, a Peritrophin-like Protein, as a New Major <i>Dermatophagoides pteronyssinus</i> Allergen Associated with the Peritrophic Matrix of Mite Fecal Pellets. <i>Journal of Immunology</i> , 2013, 190, 3059-3067.	0.8	177
48	Molecular and Immunological Characterization of Arginine Kinase from the Indianmeal Moth, <i>Plodia interpunctella</i> , a Novel Cross-Reactive Invertebrate Pan-Allergen. <i>Journal of Immunology</i> , 2001, 167, 5470-5477.	0.8	176
49	High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 3409-3420.	1.4	168
50	Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. <i>Leukemia</i> , 2018, 32, 1713-1726.	7.2	166
51	A Recombinant Hypoallergenic Parvalbumin Mutant for Immunotherapy of IgE-Mediated Fish Allergy. <i>Journal of Immunology</i> , 2007, 178, 6290-6296.	0.8	165
52	CD25 Indicates the Neoplastic Phenotype of Mast Cells. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1319-1325.	3.7	163
53	Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 3-11.	2.9	157
54	Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 110, 102-109.	2.9	156

#	ARTICLE	IF	CITATIONS
55	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	1.8	153
56	Variable presence of <i>KIT</i> ^{D816V} in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). <i>Journal of Pathology</i> , 2010, 220, 586-595.	4.5	152
57	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1125-1133.e1.	3.8	150
58	Rac2-MRC-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. <i>Blood</i> , 2012, 119, 4253-4263.	1.4	147
59	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	1.6	146
60	Severe Peripheral Arterial Disease During Nilotinib Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1347-1348.	6.3	145
61	Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML). <i>Oncotarget</i> , 2012, 3, 1588-1599.	1.8	144
62	Identification of Heme Oxygenase-1 As a Novel BCR/ABL-Dependent Survival Factor in Chronic Myeloid Leukemia. <i>Cancer Research</i> , 2004, 64, 3148-3154.	0.9	143
63	Detection of molecular targets on the surface of CD34 ⁺ /CD38 ⁺ stem cells in various myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2006, 47, 207-222.	1.3	140
64	Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. <i>Expert Review of Hematology</i> , 2012, 5, 157-176.	2.2	140
65	Time-dependent changes in mortality and transformation risk in MDS. <i>Blood</i> , 2016, 128, 902-910.	1.4	140
66	Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. <i>Journal of Clinical Oncology</i> , 2011, 29, 1963-1970.	1.6	139
67	Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. <i>European Journal of Immunology</i> , 1999, 29, 2026-2036.	2.9	138
68	Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 397-403.	2.4	138
69	Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. <i>Leukemia Research</i> , 2004, 28, 249-257.	0.8	138
70	Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. <i>Cell Research</i> , 2005, 15, 325-335.	12.0	138
71	Mutation analysis of <i>KIT</i> in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. <i>British Journal of Haematology</i> , 2001, 113, 357-364.	2.5	135
72	The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. <i>Blood</i> , 2001, 97, 3303-3305.	1.4	134

#	ARTICLE	IF	CITATIONS
73	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	1.4	132
74	Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. <i>Modern Pathology</i> , 2011, 24, 585-595.	5.5	131
75	Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. <i>Blood</i> , 2001, 98, 2200-2209.	1.4	130
76	Kit and <i>c-kit</i> Mutations in Mastocytosis: A Short Overview with Special Reference to Novel Molecular and Diagnostic Concepts. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 110-114.	2.1	130
77	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	4.6	130
78	Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. <i>Expert Review of Hematology</i> , 2010, 3, 497-516.	2.2	129
79	C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. <i>Blood</i> , 2002, 100, 517-523.	1.4	128
80	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	2.7	128
81	Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1217-1225.	2.0	126
82	Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. <i>Leukemia Research</i> , 2001, 25, 563-570.	0.8	124
83	Immunoglobulin E Response to Human Proteins in Atopic Patients. <i>Journal of Investigative Dermatology</i> , 1996, 107, 203-208.	0.7	122
84	Molecular Characterization of an Autoallergen, Hom s 1, Identified by Serum IgE from Atopic Dermatitis Patients11Part of this manuscript was previously published in the proceedings of the 21st Symposium of the Collegium Internationale Allergologicum "Allergy - A Disease of Modern Society", <i>Int Arch Allergy Immunol</i> 113:209-212, 1998. <i>Journal of Investigative Dermatology</i> , 1998, 111, 1178-1183.	0.7	122
85	Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis. <i>Cell</i> , 2011, 147, 306-319.	28.9	122
86	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	1.4	122
87	Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. <i>FASEB Journal</i> , 1998, 12, 1559-1569.	0.5	120
88	The riddle of the mast cell: kit(CD117)-ligand as the missing link?. <i>Trends in Immunology</i> , 1994, 15, 111-114.	7.5	117
89	Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. <i>FASEB Journal</i> , 2001, 15, 2042-2044.	0.5	117
90	Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. <i>Haematologica</i> , 2011, 96, 231-237.	3.5	116

#	ARTICLE	IF	CITATIONS
91	Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. FASEB Journal, 2001, 15, 2045-2047.	0.5	115
92	Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. Journal of Allergy and Clinical Immunology, 2015, 135, 1207-1217.e11.	2.9	115
93	PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nature Medicine, 2012, 18, 1699-1704.	30.7	113
94	Hereditary β -tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood, 2021, 137, 238-247.	1.4	113
95	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia, 2018, 32, 1135-1146.	7.2	112
96	Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome. International Archives of Allergy and Immunology, 2007, 142, 158-164.	2.1	111
97	Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117/Kit, and bcl-xL. Human Pathology, 2001, 32, 545-552.	2.0	109
98	Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine, 2016, 11, 43-57.	6.1	109
99	Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood, 2007, 109, 1678-1686.	1.4	108
100	The Mastocytosis Society Survey on Mast Cell Disorders: Patient Experiences and Perceptions. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 70-76.	3.8	107
101	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics, 2020, 10, 10743-10768.	10.0	107
102	How I treat patients with advanced systemic mastocytosis. Blood, 2010, 116, 5812-5817.	1.4	106
103	Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7. FASEB Journal, 1999, 13, 843-856.	0.5	105
104	Further Characterization of Surface Membrane Structures Expressed on Human Basophils and Mast Cells. International Archives of Allergy and Immunology, 1990, 91, 198-203.	2.1	102
105	Clinical and Biologic Diversity of Leukemias Occurring in Patients with Mastocytosis. Leukemia and Lymphoma, 2000, 37, 473-486.	1.3	101
106	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematology, 2019, 6, e638-e649.	4.6	101
107	Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1998, 41, 233-245.	6.7	100
108	Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thrombosis Research, 2005, 115, 59-64.	1.7	99

#	ARTICLE	IF	CITATIONS
109	Molecular characterization of dog albumin as a cross-reactive allergen. <i>Journal of Allergy and Clinical Immunology</i> , 1994, 93, 614-627.	2.9	98
110	Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. <i>Blood</i> , 2008, 112, 2463-2473.	1.4	97
111	Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. <i>Blood</i> , 2017, 130, 137-145.	1.4	97
112	Identification of common allergenic structures in mugwort and ragweed pollen. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 101, 196-206.	2.9	96
113	Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. <i>Nature Chemical Biology</i> , 2012, 8, 905-912.	8.0	96
114	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. <i>Blood</i> , 2016, 127, 2890-2902.	1.4	96
115	Der p 11 Is a Major Allergen for House Dust Mite-Allergic Patients Suffering from Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2015, 135, 102-109.	0.7	93
116	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	3.5	93
117	Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. <i>Haematologica</i> , 2007, 92, 1451-1459.	3.5	92
118	A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1562-1570.e6.	2.9	92
119	Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: The diagnostic interface. <i>Leukemia Research</i> , 2007, 31, 1461-1468.	0.8	90
120	Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features. <i>Leukemia Research</i> , 2015, 39, 1-5.	0.8	90
121	Diagnostic Criteria and Classification of Mastocytosis in 2014. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 207-218.	1.9	89
122	Adapting forest management to climate change in Europe: Linking perceptions to adaptive responses. <i>Forest Policy and Economics</i> , 2018, 90, 22-30.	3.4	87
123	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2019, 180, 44-51.	2.1	87
124	Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536. <i>Cancer Research</i> , 2010, 70, 1513-1523.	0.9	86
125	Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. <i>Blood</i> , 2008, 111, 2200-2210.	1.4	85
126	Phenotypic Characterization of Human Skin Mast Cells by Combined Staining with Toluidine Blue and CD Antibodies. <i>Journal of Investigative Dermatology</i> , 1998, 111, 689-695.	0.7	84

#	ARTICLE	IF	CITATIONS
127	Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 435-443.e4.	2.9	84
128	The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. <i>Haematologica</i> , 2017, 102, 1035-1043.	3.5	84
129	A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 1010-1016.	2.9	83
130	Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. <i>Leukemia Research</i> , 2011, 36, 1-5.	0.8	83
131	Mapping of Conformational IgE Epitopes with Peptide-Specific Monoclonal Antibodies Reveals Simultaneous Binding of Different IgE Antibodies to a Surface Patch on the Major Birch Pollen Allergen, Bet v 1. <i>Journal of Immunology</i> , 2011, 186, 5333-5344.	0.8	82
132	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2846-2856.	1.6	82
133	Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. <i>Wiener Klinische Wochenschrift</i> , 2008, 120, 136-151.	1.9	81
134	Molecular Aspects of Allergens and Allergy. <i>Advances in Immunology</i> , 2018, 138, 195-256.	2.2	81
135	Low-Level Expression of Proapoptotic Bcl-2 Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Underlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds. <i>Cancer Research</i> , 2005, 65, 9436-9444.	0.9	80
136	A Combination Vaccine for Allergy and Rhinovirus Infections Based on Rhinovirus-Derived Surface Protein VP1 and a Nonallergenic Peptide of the Major Timothy Grass Pollen Allergen Phl p 1. <i>Journal of Immunology</i> , 2009, 182, 6298-6306.	0.8	80
137	A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. <i>Blood</i> , 2014, 124, 111-120.	1.4	80
138	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. <i>Journal of Hematology and Oncology</i> , 2015, 8, 16.	17.0	80
139	Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. <i>Haematologica</i> , 2008, 93, 447-450.	3.5	79
140	Antigens Drive Memory IgE Responses in Human Allergy via the Nasal Mucosa. <i>International Archives of Allergy and Immunology</i> , 2007, 142, 133-144.	2.1	78
141	The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. <i>Blood</i> , 2008, 111, 3097-3107.	1.4	78
142	A Human Monoclonal IgE Antibody Defines a Highly Allergenic Fragment of the Major Timothy Grass Pollen Allergen, Phl p 5: Molecular, Immunological, and Structural Characterization of the Epitope-Containing Domain. <i>Journal of Immunology</i> , 2000, 165, 3849-3859.	0.8	77
143	Histopathological and Immunohistochemical Aspects of Mastocytosis. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 115-117.	2.1	77
144	Indolent Systemic Mastocytosis with Elevated Serum Tryptase, Absence of Skin Lesions, and Recurrent Severe Anaphylactoid Episodes. <i>International Archives of Allergy and Immunology</i> , 2005, 136, 273-280.	2.1	77

#	ARTICLE	IF	CITATIONS
145	Neoplastic stem cells: A novel therapeutic target in clinical oncology. <i>Cancer</i> , 2006, 107, 2512-2520.	4.1	77
146	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	9.4	77
147	The c-kit Ligand Stem Cell Factor and Anti-IgE Promote Expression of Monocyte Chemoattractant Protein-1 in Human Lung Mast Cells. <i>Blood</i> , 1997, 90, 4438-4449.	1.4	76
148	Amplification of the <i>MLL</i> gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. <i>Genes Chromosomes and Cancer</i> , 2000, 27, 380-386.	2.8	76
149	Detection of Novel CD Antigens on the Surface of Human Mast Cells and Basophils. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 299-307.	2.1	76
150	Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. <i>European Journal of Immunology</i> , 2002, 32, 270-280.	2.9	76
151	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
152	Evaluation of Close-Range Photogrammetry Image Collection Methods for Estimating Tree Diameters. <i>ISPRS International Journal of Geo-Information</i> , 2018, 7, 93.	2.9	76
153	Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens. <i>Journal of Immunology</i> , 2008, 180, 5466-5476.	0.8	75
154	B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. <i>FASEB Journal</i> , 1999, 13, 1277-1290.	0.5	73
155	Conversion of grass pollen allergen-specific human IgE into a protective IgG1 antibody. <i>European Journal of Immunology</i> , 2002, 32, 2156.	2.9	73
156	Hom s 4, an IgE-Reactive Autoantigen Belonging to a New Subfamily of Calcium-Binding Proteins, Can Induce Th Cell Type 1-Mediated Autoreactivity. <i>Journal of Immunology</i> , 2005, 175, 1286-1294.	0.8	73
157	Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis. <i>American Journal of Pathology</i> , 2009, 175, 2416-2429.	3.8	72
158	Formation of Disulfide Bonds and Homodimers of the Major Cat Allergen Fel d 1 Equivalent to the Natural Allergen by Expression in <i>Escherichia coli</i> . <i>Journal of Biological Chemistry</i> , 2003, 278, 40144-40151.	3.4	71
159	Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. <i>Blood Reviews</i> , 2009, 23, 157-165.	5.7	71
160	ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. <i>Pathobiology</i> , 2019, 86, 30-38.	3.8	71
161	Spectrum of Associated Clonal Hematologic Non-Mast Cell Lineage Disorders Occurring in Patients with Systemic Mastocytosis. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 140-142.	2.1	70
162	Conversion of Der p 23, a New Major House Dust Mite Allergen, into a Hypoallergenic Vaccine. <i>Journal of Immunology</i> , 2014, 192, 4867-4875.	0.8	69

#	ARTICLE	IF	CITATIONS
163	Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. <i>Cell Reports</i> , 2018, 23, 3127-3136.	6.4	68
164	Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. <i>Leukemia Research</i> , 2001, 25, 595-602.	0.8	67
165	Characterization of 123I-vascular endothelial growth factor-binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy. <i>International Journal of Cancer</i> , 2001, 91, 789-796.	5.1	66
166	Individual Hymenoptera Venom Compounds Induce Upregulation of the Basophil Activation Marker Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 (CD203c) in Sensitized Patients. <i>International Archives of Allergy and Immunology</i> , 2002, 129, 160-168.	2.1	66
167	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. <i>Leukemia and Lymphoma</i> , 2013, 54, 472-475.	1.3	66
168	The serum tryptase test: an emerging robust biomarker in clinical hematology. <i>Expert Review of Hematology</i> , 2014, 7, 683-690.	2.2	65
169	Characterization of Human Prostate Mast Cells and Their Increase in Periprostatic Vein Thrombosis. <i>American Journal of Clinical Pathology</i> , 2001, 116, 97-106.	0.7	64
170	Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. <i>Blood</i> , 2007, 109, 3031-3041.	1.4	64
171	Systemic Mastocytosis Associated with Chronic Idiopathic Myelofibrosis. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 58-66.	2.8	64
172	KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. <i>Blood</i> , 2011, 118, 1885-1898.	1.4	64
173	Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. <i>Leukemia and Lymphoma</i> , 2011, 52, 740-744.	1.3	64
174	STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. <i>Oncotarget</i> , 2012, 3, 1669-1687.	1.8	64
175	Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. <i>European Journal of Haematology</i> , 2015, 94, 474-490.	2.2	64
176	Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2976.	4.1	64
177	Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. <i>Journal of Clinical Investigation</i> , 2017, 127, 2392-2406.	8.2	64
178	Hymenoptera-Venom-Induced Upregulation of the Basophil Activation Marker Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 3 in Sensitized Individuals. <i>International Archives of Allergy and Immunology</i> , 2001, 126, 335-342.	2.1	63
179	Generation of an Allergy Vaccine by Disruption of the Three-Dimensional Structure of the Cross-Reactive Calcium-Binding Allergen, Phl p 7. <i>Journal of Immunology</i> , 2004, 172, 5684-5692.	0.8	62
180	Delineation of target expression profiles in CD34 ⁺ /CD38 ^{hi} and CD34 ⁺ /CD38 ⁺ stem and progenitor cells in AML and CML. <i>Blood Advances</i> , 2020, 4, 5118-5132.	5.2	62

#	ARTICLE	IF	CITATIONS
181	Smouldering Mastocytosis: A Novel Subtype of Systemic Mastocytosis with Slow Progression. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 137-139.	2.1	61
182	Detection of c-kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2002, 26, 979-984.	0.8	61
183	Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: Importance for allergenic activity. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1336-1343.	2.9	61
184	Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1581-1590.e3.	2.9	61
185	Severe Life-Threatening or Disabling Anaphylaxis in Patients with Systemic Mastocytosis: A Single-Center Experience. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 399-405.	2.1	60
186	Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. <i>International Journal of Cancer</i> , 2015, 136, 2078-2090.	5.1	60
187	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016, 101, 1133-1143.	3.5	60
188	Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 1227-1241.	2.2	59
189	CD34+/CD38- stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. <i>Haematologica</i> , 2012, 97, 219-226.	3.5	59
190	Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. <i>Leukemia Research</i> , 2014, 38, 475-483.	0.8	59
191	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. <i>Blood</i> , 2017, 130, 2499-2503.	1.4	59
192	The phenotype of human eosinophils, basophils, and mast cells. <i>Journal of Allergy and Clinical Immunology</i> , 1994, 94, 1177-1183.	2.9	58
193	Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. <i>Blood</i> , 2001, 98, 2580-2583.	1.4	58
194	Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. <i>Leukemia Research</i> , 2017, 59, 47-54.	0.8	58
195	Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. <i>British Journal of Haematology</i> , 2008, 142, 361-378.	2.5	57
196	Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. <i>Blood</i> , 2009, 114, 5342-5351.	1.4	57
197	A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreS ₁ -Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 Phenotype. <i>Journal of Immunology</i> , 2013, 190, 3068-3078.	0.8	57
198	STAT5BN642H is a driver mutation for T cell neoplasia. <i>Journal of Clinical Investigation</i> , 2017, 128, 387-401.	8.2	57

#	ARTICLE	IF	CITATIONS
199	Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growthâ€inhibitory and VEGFâ€suppressive effects of rapamycin in leukemic cells. <i>FASEB Journal</i> , 2005, 19, 960-962.	0.5	56
200	Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. <i>Blood</i> , 2010, 116, 1548-1558.	1.4	56
201	Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9030.	4.1	56
202	Expression and prognostic significance of different mRNA 5â€2â€end variants of the oncogene <i>EVI1</i> in 266 patients with de novo AML: <i>EVI1</i> and <i>MDS1/EVI1</i> overexpression both predict short remission duration. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 288-298.	2.8	55
203	Heterogeneity of Neoplastic Stem Cells: Theoretical, Functional, and Clinical Implications. <i>Cancer Research</i> , 2013, 73, 1037-1045.	0.9	55
204	The myeloma stem cell concept, revisited: from phenomenology to operational terms. <i>Haematologica</i> , 2016, 101, 1451-1459.	3.5	55
205	Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2005, 11, 6787-6792.	7.0	54
206	Tyrosine kinase inhibitorâ€induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. <i>Blood</i> , 2018, 132, 67-77.	1.4	54
207	Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. <i>The Hematology Journal</i> , 2002, 3, 90-94.	1.4	54
208	Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. <i>Molecular Immunology</i> , 2008, 45, 2486-2498.	2.2	53
209	Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 369-378.	1.7	53
210	Tumor necrosis factor β promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. <i>Arthritis and Rheumatism</i> , 2000, 43, 164-174.	6.7	52
211	Morphologic and Immunophenotypic Properties of Neoplastic Cells in a Case of Mast Cell Sarcoma. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1013-1019.	3.7	52
212	Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes. <i>Cancer</i> , 2010, 116, 2372-2381.	4.1	52
213	The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 387-400.	2.5	52
214	Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept. <i>Current Cancer Drug Targets</i> , 2011, 11, 56-71.	1.6	52
215	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. <i>Clinical Cancer Research</i> , 2016, 22, 2051-2061.	7.0	52
216	Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). <i>Oncotarget</i> , 2010, 1, 483-496.	1.8	52

#	ARTICLE	IF	CITATIONS
217	Purification of human basophils and mast cells by multistep separation technique and mAb to CDw17 and. <i>Journal of Immunological Methods</i> , 1995, 182, 115-129.	1.4	51
218	Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. <i>Haematologica</i> , 2011, 96, 163-166.	3.5	51
219	DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1239-1245.	3.4	51
220	Molecular Characterization of Polygalacturonases as Grass Pollen-Specific Marker Allergens: Expulsion from Pollen via Submicronic Respirable Particles. <i>Journal of Immunology</i> , 2004, 172, 6490-6500.	0.8	50
221	Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2006, 125, 273-281.	0.7	50
222	Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. <i>Experimental Hematology</i> , 2007, 35, 1510-1521.	0.4	50
223	Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. <i>American Journal of Hematology</i> , 2010, 85, 600-606.	4.1	50
224	Developmental, Malignancy-Related, and Cross-Species Analysis of Eosinophil, Mast Cell, and Basophil Siglec-8 Expression. <i>Journal of Clinical Immunology</i> , 2011, 31, 1045-1053.	3.8	50
225	Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. <i>Haematologica</i> , 2014, 99, 417-429.	3.5	50
226	Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 789.	4.1	50
227	Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 3071-3084.	1.8	50
228	New Aspects in Thrombotic Research: Complement Induced Switch in Mast Cells from a Profibrinolytic to a Prothrombotic Phenotype. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 438-441.	0.3	49
229	Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. <i>Leukemia Research</i> , 2007, 31, 1609-1616.	0.8	49
230	Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. <i>Clinical Chemistry</i> , 2018, 64, 547-555.	3.2	49
231	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. <i>Haematologica</i> , 2018, 103, 1593-1603.	3.5	49
232	The human basophil. <i>Critical Reviews in Oncology/Hematology</i> , 1990, 10, 327-352.	4.4	48
233	Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. <i>Blood</i> , 2001, 98, 3784-3792.	1.4	48
234	The IgE-Reactive Autoantigen Hom s 2 Induces Damage of Respiratory Epithelial Cells and Keratinocytes via Induction of IFN- β . <i>Journal of Investigative Dermatology</i> , 2008, 128, 1451-1459.	0.7	48

#	ARTICLE	IF	CITATIONS
235	Leukemic challenge unmasks a requirement for PI3K γ in NK cell-mediated tumor surveillance. <i>Blood</i> , 2008, 112, 4655-4664.	1.4	48
236	Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 252-259.	2.8	48
237	Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. <i>Veterinary Immunology and Immunopathology</i> , 2007, 115, 320-333.	1.2	47
238	Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. <i>Blood</i> , 2015, 126, 2832-2841.	1.4	47
239	Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 633-656.	9.4	47
240	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	5.7	47
241	Increase and Redistribution of Cardiac Mast Cells in Auricular Thrombosis. <i>Circulation</i> , 1995, 91, 275-283.	1.6	47
242	Delineation of Patterns of Bone Marrow Mast Cell Infiltration in Systemic Mastocytosis. <i>American Journal of Clinical Pathology</i> , 2005, 124, 560-568.	0.7	46
243	Diagnostic Evaluation and Classification of Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 515-534.	1.9	46
244	Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 1013-1016.	2.9	46
245	In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. <i>Experimental Hematology</i> , 2010, 38, 744-755.	0.4	46
246	Clinical and Laboratory Parameters of Mast Cell Activation as Basis for the Formulation of Diagnostic Criteria. <i>International Archives of Allergy and Immunology</i> , 2011, 156, 119-127.	2.1	46
247	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. <i>Blood</i> , 2016, 128, 2096-2097.	1.4	46
248	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. <i>Blood</i> , 2020, 136, 387-400.	1.4	46
249	Increased Angiogenesis in the Bone Marrow of Patients with Systemic Mastocytosis. <i>American Journal of Pathology</i> , 2002, 160, 1639-1645.	3.8	45
250	Characterization of Wild-Type Recombinant Bet v 1a as a Candidate Vaccine against Birch Pollen Allergy. <i>International Archives of Allergy and Immunology</i> , 2005, 136, 239-249.	2.1	45
251	Identification of Basophils as a Major Source of Hepatocyte Growth Factor in Chronic Myeloid Leukemia: A Novel Mechanism of BCR-ABL1-Independent Disease Progression. <i>Neoplasia</i> , 2012, 14, 572-IN10.	5.3	45
252	Overexpression of primary microRNA 221/222 in acute myeloid leukemia. <i>BMC Cancer</i> , 2013, 13, 364.	2.6	45

#	ARTICLE	IF	CITATIONS
253	The growth and differentiation of mast cells. <i>Progress in Growth Factor Research</i> , 1991, 3, 27-41.	1.6	44
254	Inhibition of Stem Cell Factor Dependent Formation of Human Mast Cells by Interleukin-3 and Interleukin-4. <i>International Archives of Allergy and Immunology</i> , 1994, 105, 264-268.	2.1	44
255	Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 98, 389-399.	2.9	44
256	Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. <i>British Journal of Haematology</i> , 2003, 120, 257-265.	2.5	44
257	High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming <i>KIT</i> mutation D816V. <i>Molecular Oncology</i> , 2010, 4, 335-346.	4.6	44
258	Familial hypertryptasemia with associated mast cell activation syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1448-1450.e3.	2.9	44
259	Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4233.	4.1	44
260	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. <i>Nature Communications</i> , 2021, 12, 2901.	12.8	44
261	Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 95-103.	2.9	43
262	A case of "smouldering" mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. <i>Leukemia Research</i> , 2001, 25, 627-634.	0.8	43
263	Assays for measuring in vitro basophil activation induced by recombinant allergens. <i>Methods</i> , 2004, 32, 265-270.	3.8	43
264	Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. <i>Blood</i> , 2007, 110, 661-669.	1.4	43
265	Mast cell-derived proteases control allergic inflammation through cleavage of IgE. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 197-202.	2.9	43
266	Characterization of Folded Recombinant Der p 5, a Potential Diagnostic Marker Allergen for House Dust Mite Allergy. <i>International Archives of Allergy and Immunology</i> , 2008, 147, 101-109.	2.1	43
267	MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. <i>Nature Communications</i> , 2018, 9, 1983.	12.8	43
268	Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 11600-11613.	1.8	43
269	Tryptase a Novel Biochemical Marker of Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 2257-2261.	1.3	42
270	In Human Macrophages the Complement Component C5a Induces the Expression of Oncostatin M via AP-1 Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 498-503.	2.4	42

#	ARTICLE	IF	CITATIONS
271	Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology American Society of Hematology Education Program, 2012, 2012, 485-491.	2.5	42
272	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 81-87.	3.8	42
273	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2020, 146, 356-366.e4.	2.9	42
274	Mast Cell-Lineage Versus Basophil Lineage Involvement in Myeloproliferative and Myelodysplastic Syndromes: Diagnostic Role of Cell-Immunopheno typing. Leukemia and Lymphoma, 1996, 22, 187-204.	1.3	41
275	Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leukemia and Lymphoma, 2006, 47, 451-460.	1.3	41
276	5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood, 2012, 119, 4242-4252.	1.4	41
277	Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFR α . Experimental Hematology, 2014, 42, 282-293.e4.	0.4	41
278	Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML. Blood, 2013, 122, 257-257.	1.4	41
279	Evaluation of Angiogenesis and Vascular Endothelial Growth Factor Expression in the Bone Marrow of Patients with Aplastic Anemia. American Journal of Pathology, 2006, 168, 123-130.	3.8	40
280	Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. Journal of Allergy and Clinical Immunology, 2010, 126, 1024-1031.e8.	2.9	40
281	Identification of oncostatin M as a JAK2 V617F α -dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB Journal, 2012, 26, 894-906.	0.5	40
282	Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. Mediators of Inflammation, 2015, 2015, 1-17.	3.0	40
283	Twins with different personalities: STAT5B α but not STAT5A α has a key role in BCR/ABL-induced leukemia. Leukemia, 2019, 33, 1583-1597.	7.2	40
284	What Have Mast Cells To Do with Edema Formation, the Consecutive Repair and Fibrinolysis?. International Archives of Allergy and Immunology, 1998, 115, 2-8.	2.1	39
285	Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leukemia and Lymphoma, 2007, 48, 1997-2007.	1.3	39
286	Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Review of Hematology, 2010, 3, 665-673.	2.2	39
287	Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica, 2013, 98, 1450-1457.	3.5	39
288	Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. Hematology American Society of Hematology Education Program, 2015, 2015, 98-105.	2.5	39

#	ARTICLE	IF	CITATIONS
289	Mast Cells, Mastocytosis, and Related Disorders. <i>New England Journal of Medicine</i> , 2015, 373, 1884-1886.	27.0	39
290	Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1009.	4.1	39
291	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. <i>Lancet Haematology</i> , 2021, 8, e194-e204.	4.6	39
292	Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia. <i>Oncotarget</i> , 2014, 5, 9564-9576.	1.8	39
293	Cytokines involved in growth and differentiation of human basophils and mast cells. <i>Experimental Dermatology</i> , 1995, 4, 255-259.	2.9	38
294	Amplification of the AML1(CBFA2) gene on ring chromosomes in a patient with acute myeloid leukemia and a constitutional ring chromosome 21. <i>Cancer Genetics and Cytogenetics</i> , 2001, 124, 42-46.	1.0	38
295	Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. <i>Leukemia Research</i> , 2001, 25, 287-294.	0.8	38
296	IFN- γ enhanced allergen penetration across respiratory epithelium augments allergic inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 973-981.	2.9	38
297	Second line BCR/ABK TKI-associated severe adverse events:preferential occurrence in patients with comorbidities. <i>Haematologica</i> , 2011, 96, 1395-7.	3.5	38
298	Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2586.	4.1	38
299	Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFR1 \pm , classification by WHO criteria, and response to therapy with imatinib. <i>Leukemia Research</i> , 2006, 30, 1201-1205.	0.8	37
300	Impact of Age and Comorbidity in Myelodysplastic Syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 927-934.	4.9	37
301	Diagnosis, progression patterns and prognostication in mastocytosis. <i>Expert Review of Hematology</i> , 2012, 5, 261-274.	2.2	37
302	Frequent occurrence of T β cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 601-609.e8.	2.9	37
303	Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic Mastocytosis. <i>American Journal of Pathology</i> , 2011, 178, 2344-2356.	3.8	36
304	A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the tyrosine kinase inhibitor imatinib in elderly patients with refractory/relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 163, 214-222.	2.5	36
305	Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 836-845.e11.	2.9	36
306	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 175-184.	1.6	36

#	ARTICLE	IF	CITATIONS
307	Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1519-1529.	3.5	36
308	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2003, 119, 663-671.	0.7	35
309	H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. <i>Experimental Hematology</i> , 2010, 38, 896-907.	0.4	35
310	Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. <i>Molecular Oncology</i> , 2010, 4, 150-160.	4.6	35
311	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1999-2012.e6.	3.8	35
312	Chronic Myelogenous Leukemia and Myeloproliferative Disease. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 146-162.	2.5	34
313	Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. <i>Experimental Hematology</i> , 2007, 35, 108-116.	0.4	34
314	Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. <i>British Journal of Haematology</i> , 2013, 160, 618-629.	2.5	34
315	High Precision Individual Tree Diameter and Perimeter Estimation from Close-Range Photogrammetry. <i>Forests</i> , 2018, 9, 696.	2.1	34
316	Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1109-1114.	3.8	34
317	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020, 34, 1090-1101.	7.2	34
318	Mastocytosis – A Disease of the Hematopoietic Stem Cell. <i>Deutsches Ärzteblatt International</i> , 2008, 105, 686-92.	0.9	34
319	Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer. <i>Molecular Immunology</i> , 2011, 48, 431-441.	2.2	33
320	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 807-814.	1.9	33
321	A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. <i>Nature Communications</i> , 2019, 10, 4741.	12.8	33
322	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3918-3928.	3.8	33
323	Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 1999, 118, 218-219.	2.1	32
324	A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. <i>Leukemia Research</i> , 2002, 26, 601-606.	0.8	32

#	ARTICLE	IF	CITATIONS
325	Gain of structure and IgE epitopes by eukaryotic expression of the major Timothy grass pollen allergen, Phl p 1. FEBS Journal, 2005, 272, 217-227.	4.7	32
326	The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. Journal of Leukocyte Biology, 2013, 95, 95-104.	3.3	32
327	Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood, 2016, 127, 2131-2143.	1.4	32
328	Phenotyping and Target Expression Profiling of CD34+/CD38 ^{low} and CD34+/CD38 ⁺ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. Neoplasia, 2018, 20, 632-642.	5.3	32
329	A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2461-2478.	5.7	32
330	Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 583-593.	5.7	32
331	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematology, 2021, 8, e135-e148.	4.6	32
332	Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity. Seminars in Immunopathology, 2021, 43, 423-438.	6.1	32
333	JAK-STAT core cancer pathway: An integrative cancer interactome analysis. Journal of Cellular and Molecular Medicine, 2022, 26, 2049-2062.	3.6	32
334	In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-Octreotide (OCT), 123I-Tyr-3-OCT and 111In-TIRA-d-Phe-1-OCT. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1388-1399.	2.1	31
335	Bone Marrow Microvessel Density and its Prognostic Significance in AML. Leukemia and Lymphoma, 2004, 45, 1369-1373.	1.3	31
336	Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications. Experimental Hematology, 2017, 51, 17-24.	0.4	31
337	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2139-2144.	3.8	31
338	Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. Oncotarget, 2016, 7, 33016-33024.	1.8	31
339	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Chronic Myeloid Leukemia and Correlation With the Phase of Disease. American Journal of Clinical Pathology, 2004, 121, 473-481.	0.7	30
340	Eosinophilia in systemic mastocytosis: Clinical and molecular correlates and prognostic significance. Journal of Allergy and Clinical Immunology, 2007, 120, 192-199.	2.9	30
341	Comparison of a Treatment Strategy Combining CCI-779 Plus DTIC Versus DTIC Monotreatment in Human Melanoma in SCID Mice. Journal of Investigative Dermatology, 2007, 127, 2411-2417.	0.7	30
342	Mastocytosis. Immunology and Allergy Clinics of North America, 2014, 34, 315-321.	1.9	30

#	ARTICLE	IF	CITATIONS
343	Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen. <i>PLoS ONE</i> , 2016, 11, e0160641.	2.5	30
344	The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. <i>Haematologica</i> , 2018, 103, 799-809.	3.5	30
345	Characterization of IgE-Reactive Autoantigens in Atopic Dermatitis 1. Subcellular Distribution and Tissue-Specific Expression. <i>International Archives of Allergy and Immunology</i> , 1999, 120, 108-116.	2.1	29
346	Activation of Human Mast Cells through Stem Cell Factor Receptor (KIT) Is Associated with Expression of bcl-2. <i>International Archives of Allergy and Immunology</i> , 2002, 129, 228-236.	2.1	29
347	Chronic myeloid leukemia: Pathophysiology, diagnostic parameters, and current treatment concepts. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 485-504.	1.9	29
348	Alleukemic Mast Cell Leukemia with Abnormal Immunophenotype and C-kit Mutation D816V. <i>Leukemia and Lymphoma</i> , 2004, 45, 2295-2302.	1.3	29
349	Bone Marrow Mastocytosis Associated with IgM Kappa Plasma Cell Myeloma. <i>Leukemia and Lymphoma</i> , 2004, 45, 801-805.	1.3	29
350	A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. <i>Biological Chemistry</i> , 2008, 389, 925-33.	2.5	29
351	Neoplastic stem cells: Current concepts and clinical perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 79-98.	4.4	29
352	Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. <i>Vaccine</i> , 2011, 29, 2140-2148.	3.8	29
353	Quantification of human diamine oxidase. <i>Clinical Biochemistry</i> , 2017, 50, 444-451.	1.9	29
354	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1124-1134.	7.2	29
355	CDK6 coordinates JAK2V617F mutant MPN via NF- κ B and apoptotic networks. <i>Blood</i> , 2019, 133, 1677-1690.	1.4	29
356	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2022, 36, 516-524.	7.2	29
357	The immunoglobulin-like modules C μ 3 and I μ 2 are the minimal units necessary for human IgE-Fc μ R1 interaction. <i>Journal of Clinical Investigation</i> , 1999, 103, 1571-1578.	8.2	29
358	The Immunoglobulin E-Allergen Interaction: A Target for Therapy of Type I Allergic Diseases. <i>International Archives of Allergy and Immunology</i> , 1998, 116, 167-176.	2.1	28
359	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020, 136, 698-714.	1.4	28
360	Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3121-3127.e1.	3.8	28

#	ARTICLE	IF	CITATIONS
361	Standards and impact of hematopathology in myelodysplastic syndromes (MDS). <i>Oncotarget</i> , 2010, 1, 483-96.	1.8	28
362	KIT as a master regulator of the mast cell lineage. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1845-1854.	2.9	28
363	Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3. <i>Journal of Leukocyte Biology</i> , 2003, 73, 107-117.	3.3	27
364	CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. <i>Leukemia and Lymphoma</i> , 2005, 46, 1115-1120.	1.3	27
365	Urticaria pigmentosa and mastocytosis: The role of immunophenotyping in diagnosis and determining response to treatment. <i>Current Allergy and Asthma Reports</i> , 2006, 6, 282-288.	5.3	27
366	Genetic Engineering of the Major Timothy Grass Pollen Allergen, Phl p 6, to Reduce Allergenic Activity and Preserve Immunogenicity. <i>Journal of Immunology</i> , 2007, 179, 1730-1739.	0.8	27
367	A Hypoallergenic Vaccine Obtained by Tail-to-Head Restructuring of Timothy Grass Pollen Profilin, Phl p 12, for the Treatment of Cross-Sensitization to Profilin. <i>Journal of Immunology</i> , 2007, 179, 7624-7634.	0.8	27
368	The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. <i>Molecular Oncology</i> , 2008, 2, 272-281.	4.6	27
369	NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. <i>British Journal of Haematology</i> , 2010, 148, 868-878.	2.5	27
370	Mast cell activation syndrome: Importance of consensus criteria and call for research. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1008-1010.	2.9	27
371	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. <i>Haematologica</i> , 2020, 105, 435-447.	3.5	27
372	Disruption of Allergenic Activity of the Major Grass Pollen Allergen Phl p 2 by Reassembly as a Mosaic Protein. <i>Journal of Immunology</i> , 2008, 181, 4864-4873.	0.8	26
373	Role of interleukins in the regulation of basophil development and secretion. <i>Current Opinion in Hematology</i> , 2010, 17, 60-66.	2.5	26
374	Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML. <i>Clinical Cancer Research</i> , 2014, 20, 3589-3602.	7.0	26
375	BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. <i>Haematologica</i> , 2018, 103, e10-e12.	3.5	26
376	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021, 11, 292-303.	10.0	26
377	Low blood counts: immune mediated, idiopathic, or myelodysplasia. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 485-91.	2.5	26
378	Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. <i>Blood</i> , 2014, 124, 955-955.	1.4	26

#	ARTICLE	IF	CITATIONS
379	Immunophenotypic and functional characterization of human tonsillar mast cells. <i>Journal of Leukocyte Biology</i> , 1997, 61, 592-599.	3.3	25
380	Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. <i>Human Pathology</i> , 1999, 30, 188-194.	2.0	25
381	Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. <i>Blood</i> , 2002, 99, 4246-4247.	1.4	25
382	A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2004, 10, 3965-3971.	7.0	25
383	Cell Surface Membrane Antigen Phenotype of Human Gastrointestinal Mast Cells. <i>International Archives of Allergy and Immunology</i> , 2005, 138, 111-120.	2.1	25
384	Allergen cleavage by effector cell-derived proteases regulates allergic inflammation. <i>FASEB Journal</i> , 2006, 20, 967-969.	0.5	25
385	ICON: Eosinophil Disorders. <i>World Allergy Organization Journal</i> , 2012, 5, 174-181.	3.5	25
386	BRD4: A BET(ter) target for the treatment of AML?. <i>Cell Cycle</i> , 2014, 13, 689-690.	2.6	25
387	Targeting the JAK2-STAT5 pathway in CML. <i>Blood</i> , 2014, 124, 1386-1388.	1.4	25
388	The underestimated role of basophils in Ph ⁺ chronic myeloid leukaemia. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13000.	3.4	25
389	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25
390	TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. <i>Cancer Research</i> , 2021, 81, 5089-5101.	0.9	25
391	Stem Cell Factor-induced Bone Marrow Mast Cell Hyperplasia Mimicking Systemic Mastocytosis (SM): Histopathologic and Morphologic Evaluation with Special Reference to Recently Established SM-criteria. <i>Leukemia and Lymphoma</i> , 2002, 43, 575-582.	1.3	24
392	Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFR β . <i>Experimental Hematology</i> , 2008, 36, 1244-1253.	0.4	24
393	Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 635-638.	1.3	24
394	Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. <i>Journal of Geriatric Oncology</i> , 2014, 5, 299-306.	1.0	24
395	The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 1-16.	4.4	24
396	CD52 is a molecular target in advanced systemic mastocytosis. <i>FASEB Journal</i> , 2014, 28, 3540-3551.	0.5	24

#	ARTICLE	IF	CITATIONS
397	CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. <i>Blood</i> , 2017, 129, 371-382.	1.4	24
398	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24.	6.1	24
399	Thinning trainer based on forest-growth model, virtual reality and computer-aided virtual environment. <i>Environmental Modelling and Software</i> , 2018, 100, 11-23.	4.5	24
400	Thrombin Augments Vascular Cell-dependent Migration of Human Mast Cells: Role of MGF. <i>Thrombosis and Haemostasis</i> , 1997, 77, 577-584.	3.4	24
401	The PI3-Kinase/mTOR-Targeting Drug NVP-BE235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils. <i>PLoS ONE</i> , 2012, 7, e29925.	2.5	24
402	Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1783-1794.	1.6	24
403	A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-Fc ϵ RI interaction and reacts with receptor-bound IgE. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 409-416.	2.9	23
404	The European Competence Network on Mastocytosis. <i>Wiener Klinische Wochenschrift</i> , 2004, 116, 647-651.	1.9	23
405	The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. <i>Blood</i> , 2006, 108, 3538-3547.	1.4	23
406	Myelomastocytic leukemia: histopathological features, diagnostic criteria and differential diagnosis. <i>Expert Review of Hematology</i> , 2014, 7, 431-437.	2.2	23
407	Molecular Evolution of Hypoallergenic Hybrid Proteins for Vaccination against Grass Pollen Allergy. <i>Journal of Immunology</i> , 2015, 194, 4008-4018.	0.8	23
408	Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1831-1838.	1.3	23
409	Extracorporeal IgE Immunoabsorption in Allergic Asthma: Safety and Efficacy. <i>EBioMedicine</i> , 2017, 17, 119-133.	6.1	23
410	Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model. <i>Frontiers in Pharmacology</i> , 2017, 8, 319.	3.5	23
411	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 300-306.	2.9	23
412	Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2458.	4.1	23
413	Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2684.	4.1	23
414	A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. <i>Blood</i> , 2021, 138, 2347-2359.	1.4	23

#	ARTICLE	IF	CITATIONS
415	Systemic Mastocytosis. , 2008, 142, 399-419.		23
416	Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. <i>Oncotarget</i> , 2018, 9, 26491-26506.	1.8	23
417	The protein tyrosine kinase Tec regulates mast cell function. <i>European Journal of Immunology</i> , 2009, 39, 3228-3238.	2.9	22
418	Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. <i>Leukemia</i> , 2022, 36, 2108-2120.	7.2	22
419	Purification, Structural and Immunological Characterization of a Timothy Grass (<i>Phleum pratense</i>) Pollen Allergen, Phl p 4, with Cross-Reactive Potential. <i>Biological Chemistry</i> , 2002, 383, 1383-96.	2.5	21
420	Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications. <i>Leukemia and Lymphoma</i> , 2007, 48, 1900-1909.	1.3	21
421	Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. <i>Acta Dermato-Venereologica</i> , 2016, 96, 602-612.	1.3	21
422	Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. <i>European Journal of Clinical Investigation</i> , 2016, 46, 392-397.	3.4	21
423	Identification of a leukemia-initiating stem cell in human mast cell leukemia. <i>Leukemia</i> , 2019, 33, 2673-2684.	7.2	21
424	Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. <i>Haematologica</i> , 2020, 105, 366-374.	3.5	21
425	Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 411.	4.1	21
426	Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis. <i>Blood</i> , 2021, 137, 2070-2084.	1.4	21
427	High-Level Expression in <i>Escherichia coli</i> and Purification of Recombinant Plant Profilins: Comparison of IgE-Binding Capacity and Allergenic Activity. <i>Biochemical and Biophysical Research Communications</i> , 1996, 226, 42-50.	2.1	20
428	Molecular characterization of recombinant T1, a non-allergenic periwinkle (<i>Catharanthus roseus</i>) protein, with sequence similarity to the Bet v 1 plant allergen family. <i>Biochemical Journal</i> , 2003, 373, 261-269.	3.7	20
429	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. <i>Haematologica</i> , 2015, 100, 205-213.	3.5	20
430	Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. <i>Annals of Hematology</i> , 2015, 94, 223-231.	1.8	20
431	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. <i>Leukemia Research</i> , 2018, 73, 51-57.	0.8	20
432	Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. <i>Pharmacological Research</i> , 2020, 158, 104682.	7.1	20

#	ARTICLE	IF	CITATIONS
433	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1953-1963.	3.8	20
434	Division of the Major Birch Pollen Allergen, Bet v 1, into Two Non-Anaphylactic Fragments. <i>International Archives of Allergy and Immunology</i> , 1997, 113, 246-248.	2.1	19
435	IgA cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease. <i>European Journal of Immunology</i> , 2001, 31, 918-928.	2.9	19
436	Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. <i>Experimental Hematology</i> , 2008, 36, 1461-1470.	0.4	19
437	Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML. <i>European Journal of Internal Medicine</i> , 2009, 20, 775-778.	2.2	19
438	The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). <i>Blood</i> , 2010, 116, 850-851.	1.4	19
439	The impact of molecular targets in cancer drug development: major hurdles and future strategies. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 23-34.	3.1	19
440	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 837.	4.1	19
441	The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 55-68.	1.8	19
442	Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 45-57.	3.4	19
443	CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. <i>Leukemia</i> , 2019, 33, 1608-1619.	7.2	19
444	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , 2012, 120, 799-799.	1.4	19
445	Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56 ^{bright} NK cell subpopulations in patients with acute myeloid leukemia and supports their activation. <i>Oncotarget</i> , 2016, 7, 46466-46481.	1.8	19
446	Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. <i>Oncotarget</i> , 2014, 5, 1198-1211.	1.8	19
447	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1855-1865.	2.9	19
448	High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. <i>Leukemia Research</i> , 2005, 29, 609-615.	0.8	18
449	Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells. <i>Molecular Carcinogenesis</i> , 2015, 54, 789-799.	2.7	18
450	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. <i>Haematologica</i> , 2018, 103, 1760-1771.	3.5	18

#	ARTICLE	IF	CITATIONS
451	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. <i>Blood</i> , 2018, 132, 1936-1950.	1.4	18
452	Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 1-10.	1.8	18
453	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 410-418.	1.9	18
454	TGF β 2R-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. <i>Cell Reports</i> , 2020, 33, 108221.	6.4	18
455	Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. <i>Biologics: Targets and Therapy</i> , 2007, 1, 433-48.	3.2	18
456	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS&Flow</scp> Cytometry Working Group. <i>Cytometry Part B - Clinical Cytometry</i> , 2023, 104, 77-86.	1.5	18
457	Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1866-1874.	2.9	18
458	FDG Positron Emission Tomography in Patients with Systemic Mastocytosis. <i>American Journal of Roentgenology</i> , 2002, 179, 1235-1237.	2.2	17
459	Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse. <i>Clinical Cancer Research</i> , 2005, 11, 6536-6543.	7.0	17
460	Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. <i>Human Pathology</i> , 2008, 39, 917-924.	2.0	17
461	Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. <i>Veterinary Immunology and Immunopathology</i> , 2009, 132, 243-250.	1.2	17
462	Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. <i>Haematologica</i> , 2011, 96, 672-680.	3.5	17
463	Controversies and Open Questions in the Definitions and Classification of the Hypereosinophilic Syndromes and Eosinophilic Leukemias. <i>Seminars in Hematology</i> , 2012, 49, 171-181.	3.4	17
464	Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 376-382.	1.9	17
465	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I&C-CBF) Tj ETQo1 1 0.784314 rg 8T 2.8 17	2.8	17
466	Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. <i>American Journal of Cancer Research</i> , 2013, 3, 159-72.	1.4	17
467	Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1912-1918.	2.9	17
468	Does Cord Blood Contain Enough Progenitor Cells for Transplantation?. <i>Stem Cells and Development</i> , 1994, 3, 291-298.	1.0	16

#	ARTICLE	IF	CITATIONS
469	Mast cells, thrombosis, and fibrinolysis. <i>Thrombosis Research</i> , 2002, 105, 359-365.	1.7	16
470	Induction of Apoptosis in the Human Mast Cell Leukemia Cell Line HMC-1 by Various Antineoplastic Drugs. <i>Leukemia and Lymphoma</i> , 2003, 44, 509-515.	1.3	16
471	Expression of Cell Surface Antigens on Mast Cells: Mast Cell Phenotyping. , 2006, 315, 077-090.		16
472	Trimolecular Complex Formation of IgE, Fc μ RI, and a Recombinant Nonanaphylactic Single-Chain Antibody Fragment with High Affinity for IgE. <i>Journal of Immunology</i> , 2009, 182, 4817-4829.	0.8	16
473	E- and P-Selectins Are Essential for Repopulation of Chronic Myelogenous and Chronic Eosinophilic Leukemias in a Scid Mouse Xenograft Model. <i>PLoS ONE</i> , 2013, 8, e70139.	2.5	16
474	Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia. <i>Experimental Hematology</i> , 2018, 57, 50-59.e6.	0.4	16
475	The Mastocytosis Society Survey on Mast Cell Disorders: Part 2â€”Patient Clinical Experiences and Beyond. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1157-1165.e6.	3.8	16
476	COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2083-2086.	3.8	16
477	Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2006, 125, 273-281.	0.7	16
478	Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). <i>American Journal of Blood Research</i> , 2013, 3, 174-80.	0.6	16
479	Flow cytometric analysis of myelodysplasia: Preâ€”analytical and technical issuesâ€”Recommendations from the European <sc>LeukemiaNet</sc>. <i>Cytometry Part B - Clinical Cytometry</i> , 2023, 104, 15-26.	1.5	16
480	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. <i>Frontiers in Veterinary Science</i> , 2021, 8, 755258.	2.2	16
481	Splenic Mastocytosis: Report of Two Cases and Detection of the Transforming Somatic C-KIT Mutation D816V. <i>Leukemia and Lymphoma</i> , 2004, 45, 723-729.	1.3	15
482	Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?. <i>European Journal of Clinical Investigation</i> , 2010, 40, 918-931.	3.4	15
483	A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL. <i>PLoS ONE</i> , 2013, 8, e77155.	2.5	15
484	Phenotyping of Human Melanoma Cells Reveals a Unique Composition of Receptor Targets and a Subpopulation Co-Expressing ErbB4, EPO-R and NGF-R. <i>PLoS ONE</i> , 2014, 9, e84417.	2.5	15
485	Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms. <i>Seminars in Cancer Biology</i> , 2020, 60, 191-201.	9.6	15
486	Searching for Pareto Fronts for Forest Stand Wind Stability by Incorporating Timber and Biodiversity Values. <i>Forests</i> , 2020, 11, 583.	2.1	15

#	ARTICLE	IF	CITATIONS
487	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. <i>Blood</i> , 2014, 124, 636-636.	1.4	15
488	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Acute Myeloid Leukemia: Correlation Between VEGF Expression and the FAB Category. <i>American Journal of Clinical Pathology</i> , 2003, 119, 663-671.	0.7	15
489	The impact of COVID-19 on cancer care of outpatients with low socioeconomic status. <i>International Journal of Cancer</i> , 2022, 151, 77-82.	5.1	15
490	Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1998, 102, 535-543.	2.5	14
491	Autoantibody Reactivity in a Case of Schnitzler's Syndrome: Evidence for a Th1-Like Response and Detection of IgG2 Anti-Fc μ R1 \pm Antibodies. <i>International Archives of Allergy and Immunology</i> , 2000, 122, 279-286.	2.1	14
492	Targeted genes in haematology. <i>European Journal of Clinical Investigation</i> , 2004, 34, 1-1.	3.4	14
493	Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis. <i>Human Pathology</i> , 2006, 37, 439-447.	2.0	14
494	Improved Outcome in Patients with Chronic Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Over the Past 25 Years: A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 133-140.	2.0	14
495	Monoclonal B-cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal circulating B-cell subsets. <i>American Journal of Hematology</i> , 2012, 87, 721-724.	4.1	14
496	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. <i>EBioMedicine</i> , 2019, 50, 111-121.	6.1	14
497	An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 945-951.	2.5	14
498	KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6. <i>Haematologica</i> , 2020, 105, 5-6.	3.5	14
499	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1719-1727.	0.7	14
500	Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS. <i>Blood</i> , 2014, 124, 1570-1570.	1.4	14
501	BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph ⁺ chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1215-1225.	4.1	14
502	Immunophenotypic Characterization of Human Basophils and Mast Cells. <i>Chemical Immunology and Allergy</i> , 1995, 61, 34-48.	1.7	13
503	Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. <i>Leukemia Research</i> , 2005, 29, 1473-1477.	0.8	13
504	Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: A hypothesis supported by unique case reports. <i>Leukemia Research</i> , 2008, 32, 1333-1337.	0.8	13

#	ARTICLE	IF	CITATIONS
505	Lenalidomide therapy in systemic mastocytosis. <i>Leukemia Research</i> , 2009, 33, e19-e22.	0.8	13
506	Comparative analysis of IL-6 and IL-6 receptor gene polymorphisms in mastocytosis. <i>British Journal of Haematology</i> , 2013, 160, 216-219.	2.5	13
507	Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils. <i>Leukemia and Lymphoma</i> , 2013, 54, 835-842.	1.3	13
508	In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 562-567.	2.2	13
509	Functional characterization, localization, and inhibitor sensitivity of the TPR-EGFR1 fusion in 8p11 myeloproliferative syndrome. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 60-68.	2.8	13
510	Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3987.	4.1	13
511	Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 553-561.	1.8	13
512	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1705-1712.e4.	3.8	13
513	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. <i>Oncotarget</i> , 2017, 8, 23061-23072.	1.8	13
514	The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. <i>Oncotarget</i> , 2017, 8, 67709-67722.	1.8	13
515	Effects of dental amalgam and heavy metal cations on cytokine production by peripheral blood mononuclear cells in vitro. , 1998, 42, 76-84.		12
516	Amplification of ribosomal RNA genes in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 11-17.	2.8	12
517	Response to the letter of Dr. Karin Hartmann and Dr. Beate M. Henz. <i>Leukemia Research</i> , 2002, 26, 485-486.	0.8	12
518	Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. <i>Leukemia Research</i> , 2005, 29, 1227-1232.	0.8	12
519	Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. <i>Leukemia and Lymphoma</i> , 2011, 52, 1435-1445.	1.3	12
520	Eosinophil, basophil, and mast cell infiltrates in the bone marrow: crossing the boundaries of diagnosis. <i>Journal of Hematopathology</i> , 2011, 4, 101-111.	0.4	12
521	Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study. <i>Leukemia Research</i> , 2013, 37, 862-867.	0.8	12
522	Proposed score for survival of patients with myelodysplastic syndromes. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1120-1128.	3.4	12

#	ARTICLE	IF	CITATIONS
523	FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. <i>Leukemia Research Reports</i> , 2014, 3, 8-13.	0.4	12
524	Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 234-237.	1.9	12
525	Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1098-1101.	1.3	12
526	Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology. <i>Journal of Personalized Medicine</i> , 2020, 10, 94.	2.5	12
527	STAT5 is Expressed in CD34+/CD38 ⁻ Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	3.7	12
528	Core-binding factor leukemia hijacks the T-cell ⁻ prone PU.1 antisense promoter. <i>Blood</i> , 2021, 138, 1345-1358.	1.4	12
529	Transposon-mediated generation of <i>BCR-ABL1</i> -expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors. <i>Oncotarget</i> , 2016, 7, 78083-78094.	1.8	12
530	Why clinicians should be interested in Interleukin-3. <i>Blut</i> , 1990, 61, 338-345.	1.2	11
531	Characterization of LDL and VLDL Binding Sites on Human Basophils and Mast Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 17-26.	2.4	11
532	Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 897-906.	1.3	11
533	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. <i>Leukemia and Lymphoma</i> , 2020, 61, 1075-1083.	1.3	11
534	Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101137.	1.7	11
535	Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues. <i>Stem Cells Translational Medicine</i> , 2020, 9, 1331-1343.	3.3	11
536	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3025.	4.1	11
537	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. <i>HemaSphere</i> , 2021, 5, e536.	2.7	11
538	Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. <i>American Journal of Cancer Research</i> , 2011, 1, 531-41.	1.4	11
539	Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. <i>American Journal of Blood Research</i> , 2014, 4, 93-100.	0.6	11
540	Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. <i>Leukemia Research</i> , 2008, 32, 1779-1783.	0.8	10

#	ARTICLE	IF	CITATIONS
541	Interleukin-33: a regulator of basophils. <i>Blood</i> , 2009, 113, 1396-1397.	1.4	10
542	KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). <i>Experimental Hematology</i> , 2010, 38, 782-791.	0.4	10
543	Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥ 60 years) who benefit from intensive post-induction consolidation therapy. <i>American Journal of Hematology</i> , 2016, 91, 1239-1245.	4.1	10
544	Variability of PD-L1 expression in mastocytosis. <i>Blood Advances</i> , 2018, 2, 189-199.	5.2	10
545	Results from a Genome-Wide Association Study (GWAS) in Mastocytosis Reveal New Gene Polymorphisms Associated with WHO Subgroups. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5506.	4.1	10
546	Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. <i>European Journal of Haematology</i> , 2021, 107, 265-274.	2.2	10
547	Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 ($JAK2$) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. <i>British Journal of Haematology</i> , 2021, 194, 344-354.	2.5	10
548	Expression of fibrinolytic antigens in redistributed cardiac mast cells in auricular thrombosis. <i>Human Pathology</i> , 1997, 28, 1283-1290.	2.0	9
549	Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 507-516.	1.9	9
550	Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRP α), CD47, and SHP-1. <i>Journal of Leukocyte Biology</i> , 2005, 77, 984-992.	3.3	9
551	Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. <i>Wiener Klinische Wochenschrift</i> , 2008, 120, 697-709.	1.9	9
552	The Transcription Factor MAZR Preferentially Acts as a Transcriptional Repressor in Mast Cells and Plays a Minor Role in the Regulation of Effector Functions in Response to Fc ϵ RI Stimulation. <i>PLoS ONE</i> , 2013, 8, e77677.	2.5	9
553	Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥ 60 years. <i>American Journal of Hematology</i> , 2017, 92, E567-E574.	4.1	9
554	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. <i>Future Oncology</i> , 2018, 14, 2713-2723.	2.4	9
555	miRNome profiling of LSC-enriched CD34 ⁺ CD38 ⁺ CD26 ⁺ fraction in Ph ⁺ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool. <i>Frontiers in Pharmacology</i> , 2020, 11, 612573.	3.5	9
556	Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib. <i>Blood</i> , 2016, 128, 1883-1883.	1.4	9
557	Update on genetic and molecular markers associated with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2009, 50, 341-348.	1.3	8
558	Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet "pre-leukemic" stem cells?. <i>Leukemia and Lymphoma</i> , 2011, 52, 842-848.	1.3	8

#	ARTICLE	IF	CITATIONS
559	Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 370-377.	4.4	8
560	Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 809-817.	2.8	8
561	cFinder: definition and quantification of multiple haplotypes in a mixed sample. <i>BMC Research Notes</i> , 2015, 8, 422.	1.4	8
562	Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 490-493.e11.	2.9	8
563	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. <i>Hematological Oncology</i> , 2019, 37, 240-252.	1.7	8
564	Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2761-2768.e16.	3.8	8
565	A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1454.	4.1	8
566	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 3176-3187.	7.2	8
567	Recombinant Allergens. <i>Advances in Experimental Medicine and Biology</i> , 1996, , 185-196.	1.6	8
568	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Chronic Myeloid Leukemia and Correlation With the Phase of Disease. <i>American Journal of Clinical Pathology</i> , 2004, 121, 473-481.	0.7	8
569	Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial. <i>Blood</i> , 2008, 112, 2973-2973.	1.4	8
570	PD-L1 overexpression correlates with JAK2V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 390-400.	4.1	8
571	Immunophenotypic Analysis of HL-60 Cells during Basophilic Differentiation. <i>International Archives of Allergy and Immunology</i> , 1996, 110, 252-260.	2.1	7
572	Detection of Trisomy 8 in Donor-Derived Ph ⁺ Cells in a Patient with Ph ⁺ Chronic Myeloid Leukemia Successfully Treated with Imatinib (STI571) in Relapse after Allogeneic Transplantation. <i>Leukemia and Lymphoma</i> , 2004, 45, 1453-1458.	1.3	7
573	Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes. <i>Clinical Leukemia</i> , 2007, 1, 353-356.	0.2	7
574	A patient with de novo AML M1 and t(16;21) with karyotype evolution. <i>Leukemia Research</i> , 2007, 31, 1319-1321.	0.8	7
575	Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 604-609.	1.3	7
576	Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?. <i>American Journal of Hematology</i> , 2013, 88, 533-534.	4.1	7

#	ARTICLE	IF	CITATIONS
577	Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 119-125.	1.9	7
578	Dasatinib-induced immunosuppression and recurrent respiratory tract infections. <i>Leukemia and Lymphoma</i> , 2015, 56, 2484-2485.	1.3	7
579	Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for venoocclusive disease?. <i>European Journal of Haematology</i> , 2016, 96, 655-657.	2.2	7
580	Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL. <i>Cells</i> , 2020, 9, 1484.	4.1	7
581	Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 487-498.	3.1	7
582	Forest modelling and visualisation – state of the art and perspectives. <i>Central European Forestry Journal</i> , 2019, 65, 147-165.	0.8	7
583	Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinite growth in colon cancer cells. <i>American Journal of Cancer Research</i> , 2015, 5, 560-74.	1.4	7
584	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. <i>Nature Communications</i> , 2021, 12, 7190.	12.8	7
585	The cancer survival index – A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. <i>Cancer Medicine</i> , 2022, 11, 3387-3396.	2.8	7
586	Signal Transduction-Associated and Cell Activation-Linked Antigens Expressed in Human Mast Cells. <i>International Journal of Hematology</i> , 2002, 75, 357-362.	1.6	6
587	Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype. <i>Leukemia Research</i> , 2004, 28, 651-655.	0.8	6
588	Expression of a Major Plant Allergen as Membrane-Anchored and Secreted Protein in Human Cells with Preserved T Cell and B Cell Epitopes. <i>International Archives of Allergy and Immunology</i> , 2011, 156, 259-266.	2.1	6
589	<i>In vitro</i> effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells. <i>Veterinary Medicine and Science</i> , 2021, 7, 57-68.	1.6	6
590	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6
591	Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2964.	4.1	6
592	Culturing cells with mast cell phenotype and function: Comparison of peripheral blood and bone marrow as a source.. <i>Journal of Immunological Methods</i> , 2021, 495, 113061.	1.4	6
593	Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib. <i>Blood</i> , 2007, 110, 1541-1541.	1.4	6
594	Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML. <i>Blood</i> , 2011, 118, 2753-2753.	1.4	6

#	ARTICLE	IF	CITATIONS
595	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. <i>Blood</i> , 2013, 122, 106-106.	1.4	6
596	Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia. <i>Blood</i> , 2014, 124, 817-817.	1.4	6
597	Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single hit^{TM} and cooperate in producing a mastocytosis-like disease in mice. <i>Oncotarget</i> , 2010, 1, 104-119.	1.8	6
598	Evaluation of <i>in vitro</i> effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. <i>Oncotarget</i> , 2016, 7, 65627-65642.	1.8	6
599	The c-kit Ligand Stem Cell Factor and Anti-IgE Promote Expression of Monocyte Chemoattractant Protein-1 in Human Lung Mast Cells. <i>Blood</i> , 1997, 90, 4438-4449.	1.4	6
600	Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance. <i>Blood</i> , 2021, 138, 1481-1481.	1.4	6
601	Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. <i>Medical and Pediatric Oncology</i> , 1992, 20, 18-22.	1.0	5
602	Treatment concepts for elderly patients with acute myeloid leukemia. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 505-514.	1.9	5
603	Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5. <i>Journal of Immunology</i> , 2006, 176, 1759-1768.	0.8	5
604	Biology and clinical features of myeloid neoplasms with inv(3) (q21q26) or t(3;3) (q21q26). <i>Leukemia and Lymphoma</i> , 2007, 48, 2096-2097.	1.3	5
605	Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy. <i>Immunobiology</i> , 2013, 218, 1155-1165.	1.9	5
606	Mast cell leukemia: a review. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 395-405.	1.6	5
607	A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) $\hat{=}$ “ AGMT_CMML-1. <i>Leukemia and Lymphoma</i> , 2018, 59, 1121-1126.	1.3	5
608	Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6057.	4.1	5
609	BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML. <i>Blood</i> , 2018, 132, 1722-1722.	1.4	5
610	Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML. <i>Blood</i> , 2014, 124, 1800-1800.	1.4	5
611	A Novel Fusion Gene NDEL1-Pdgfrb in a Patient with JMML with a New Variant of TKI-Resistant Mutation in the Kinase Domain of PDGFRI ² . <i>Blood</i> , 2014, 124, 613-613.	1.4	5
612	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 609-609.	1.4	5

#	ARTICLE	IF	CITATIONS
613	Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML. American Journal of Cancer Research, 2015, 5, 354-62.	1.4	5
614	A series of case studies illustrating the role of flow cytometry in the diagnostic workâ€up of myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2022, , .	1.5	5
615	Overexpression of FcÎµRI on Bone Marrow Mast Cells, but Not MRGPRX2, in Clonal Mast Cell Disorders With Wasp Venom Anaphylaxis. Frontiers in Immunology, 2022, 13, 835618.	4.8	5
616	Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). Wiener Klinische Wochenschrift, 2003, 115, 515-536.	1.9	4
617	Mast cells, masters, and mastocytosis: Development of research since the times of Paul Ehrlich. Wiener Klinische Wochenschrift, 2004, 116, 645-646.	1.9	4
618	An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase. European Journal of Haematology, 2005, 75, 73-77.	2.2	4
619	First annual report of the Austrian CML registry. Wiener Klinische Wochenschrift, 2010, 122, 558-566.	1.9	4
620	Diagnosis and Treatment of Anaphylaxis in Patients with Mastocytosis. Current Treatment Options in Allergy, 2014, 1, 247-261.	2.2	4
621	Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm. Wiener Klinische Wochenschrift, 2017, 129, 404-410.	1.9	4
622	Switching From Highâ€Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report. HemaSphere, 2020, 4, e455.	2.7	4
623	Physiology and pathology of eosinophils: Recent developments. Scandinavian Journal of Immunology, 2021, 93, e13032.	2.7	4
624	Metabolome and lipidome derangements during a severe mast cell activation event in a patient with indolent systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2021, 148, 1533-1544.	2.9	4
625	Role of Mast Cells in Endogenous Fibrinolysis and Related (Patho)physiological Processes. , 2000, , 497-505.		4
626	c-kit D816V Provides a Strong Signal for Myelomastocytic Differentiation and Cluster Formation in Murine Ba/F3 Cells.. Blood, 2004, 104, 485-485.	1.4	4
627	Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.. Blood, 2006, 108, 252-252.	1.4	4
628	Nilotinib and Imatinib Are Comparably Effective in Reducing Growth of Human Eosinophil Leukemia Cells in a Newly Established Xenograft Model. PLoS ONE, 2012, 7, e30567.	2.5	4
629	An in vitro Model for the Allergenâ€“IgEâ€“FcÎµRI Interaction. International Archives of Allergy and Immunology, 1999, 118, 116-118.	2.1	3
630	Classification and Response Criteria in Mast Cell Disorders: Time to Revise?. International Archives of Allergy and Immunology, 2011, 155, 306-308.	2.1	3

#	ARTICLE	IF	CITATIONS
631	Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 23-29.	1.9	3
632	Clofarabine/cyclophosphamide for debulking before stem cell transplantation. <i>European Journal of Clinical Investigation</i> , 2014, 44, 775-783.	3.4	3
633	Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. <i>Expert Review of Hematology</i> , 2018, 11, 109-116.	2.2	3
634	The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 137-139.	2.5	3
635	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 547-556.	2.8	3
636	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 517-529.	1.9	3
637	A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T3151 in Ph+ CML. <i>Leukemia Research</i> , 2019, 78, 36-44.	0.8	3
638	Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. <i>Cancers</i> , 2020, 12, 1891.	3.7	3
639	Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival. <i>European Journal of Haematology</i> , 2021, 106, 627-633.	2.2	3
640	Overexpression of PD-L1 Correlates with JAK2-V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN. <i>Blood</i> , 2020, 136, 24-24.	1.4	3
641	New and Comprehensive Cytogenetic Prognostication and Categorization in MDS. <i>Blood</i> , 2006, 108, 248-248.	1.4	3
642	Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 3681-3681.	1.4	3
643	Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 945-945.	1.4	3
644	Structural and mutational analysis of ember-specific STAT junctions. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2022, 1866, 130058.	2.4	3
645	Forest land tax reductions – an effective payment for forest ecosystem services in Slovakia?. <i>Central European Forestry Journal</i> , 2021, 67, 167-176.	0.8	3
646	Multistep pathogenesis of chronic myelomonocytic leukemia in patients. <i>European Journal of Haematology</i> , 2022, , .	2.2	3
647	Massive release of TH2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 406-414.e16.	2.9	3
648	Reciprocal Translocation (3;5)(q26;q22) and Possible BCHE Gene Involvement in an Unusual Myelogenous Disorder with both Myeloproliferative and Dysplastic Features. <i>Cancer Genetics and Cytogenetics</i> , 2000, 121, 133-138.	1.0	2

#	ARTICLE	IF	CITATIONS
649	Use of interleukin-11 to stimulate platelet production in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2006, 47, 1999-2001.	1.3	2
650	Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia. <i>Lancet Oncology</i> , The, 2010, 11, 1010-1011.	10.7	2
651	Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 354-358.	1.9	2
652	Glucocorticosteroids Rescue Basophils from Dasatinib-Augmented Immunoglobulin E-Mediated Histamine Release. <i>International Archives of Allergy and Immunology</i> , 2012, 159, 15-22.	2.1	2
653	Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. <i>American Journal of Hematology</i> , 2021, 96, E207-E210.	4.1	2
654	Mastocytosis, MCAS, and Related Disorders—Diagnosis, Classification, and Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5024.	4.1	2
655	Case report of a clinically indolent but morphologically high-grade cutaneous mast cell tumor in an adult: atypical cutaneous mastocytoma or mast cell sarcoma?. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1404-1409.	1.3	2
656	The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest. <i>Blood</i> , 2018, 132, 1363-1363.	1.4	2
657	Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.. <i>Blood</i> , 2005, 106, 3518-3518.	1.4	2
658	New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics. <i>Blood</i> , 2008, 112, 2688-2688.	1.4	2
659	Serum Tryptase Is a Strong Predictive Biomarker That Improves Prognostication in Ph+ Chronic Myeloid Leukemia.. <i>Blood</i> , 2012, 120, 2783-2783.	1.4	2
660	Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated Dual Synthetic Lethality To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells. <i>Blood</i> , 2013, 122, 810-810.	1.4	2
661	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. <i>Blood</i> , 2014, 124, 1881-1881.	1.4	2
662	Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 2284-2284.	1.4	2
663	Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 943-943.	1.4	2
664	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. <i>Blood</i> , 2015, 126, 4085-4085.	1.4	2
665	Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors. <i>Blood</i> , 2016, 128, 3109-3109.	1.4	2
666	Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC. <i>Blood</i> , 2016, 128, 4234-4234.	1.4	2

#	ARTICLE	IF	CITATIONS
667	Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 947-947.	1.4	2
668	Mast cells and mast cell growth factor: possible role in auricular thrombosis. <i>Biomedical Reviews</i> , 2014, 4, 29.	0.6	2
669	Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice. <i>Oncotarget</i> , 2010, 1, 104-19.	1.8	2
670	Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 530-545.	1.4	2
671	Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing -compound mutations. <i>American Journal of Cancer Research</i> , 2021, 11, 4470-4484.	1.4	2
672	Refinements in Response Criteria in Systemic Mastocytosis: Reply to a Proposal. <i>European Journal of Haematology</i> , 2010, 85, no-no.	2.2	1
673	Endogenous Erythroid Colony Formation in Chronic Myeloid Leukemia: A Recurrent Finding Associated with Persistent Minimal Residual Disease Under Imatinib. <i>Stem Cells and Development</i> , 2013, 22, 3043-3051.	2.1	1
674	Characterization and targeting of neoplastic stem cells in Ph+chronic myeloid leukemia. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 151-165.	1.6	1
675	All systems red. <i>American Journal of Hematology</i> , 2015, 90, 356-360.	4.1	1
676	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 12-15.	1.9	1
677	Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?. <i>Haematologica</i> , 2016, 101, e492-e492.	3.5	1
678	Major response of PNH to an AML chemotherapy protocol. <i>Annals of Hematology</i> , 2018, 97, 1487-1488.	1.8	1
679	Mast Cells and Mastocytosis. , 2018, , 1170-1186.		1
680	Comparison of <i>BCR-ABL1</i> quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1214-1222.	2.3	1
681	Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. <i>American Journal of Hematology</i> , 2021, 96, 719-726.	4.1	1
682	Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. , 0, .		1
683	Systemic Mastocytosis Associated with Lymphoproliferative Disorders (SM-AHNMD). , 2012, , 271-279.		1
684	A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients. <i>Blood</i> , 2018, 132, 349-349.	1.4	1

#	ARTICLE	IF	CITATIONS
703	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 3136-3136.	1.4	1
704	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. <i>Neoplasia</i> , 2021, 23, 1183-1191.	5.3	1
705	<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. <i>Blood</i> , 2020, 136, 4-4.	1.4	1
706	Impact of interest rates on forest management planning based on multi-criteria decision analysis. <i>Central European Forestry Journal</i> , 2022, 68, 23-35.	0.8	1
707	Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 6181.	3.7	1
708	Targets and targeted drugs in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 599-599.	1.3	0
709	Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS). <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 13-17.	0.5	0
710	Classification and response criteria in mastocytosis: is there a need to revise?. <i>Expert Review of Hematology</i> , 2010, 3, 247-249.	2.2	0
711	Systemic mastocytosis. , 2012, , 369-378.		0
712	The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 114-118.	0.5	0
713	Peripheral arterial disease outcomes and association with suPAR: A bridge to myeloid precursors or mast cells or both?. <i>Atherosclerosis</i> , 2017, 264, 77-78.	0.8	0
714	Cover Image, Volume 16, Issue 1. <i>Veterinary and Comparative Oncology</i> , 2018, 16, i.	1.8	0
715	Eosinophilia, Eosinophil-Associated Diseases, Eosinophilic Leukemias, and the Hypereosinophilic Syndromes. , 2018, , 1151-1169.		0
716	Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2019, 77, 8-13.	0.8	0
717	A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 415-422.	1.9	0
718	Clinical Course and Prognosis in Mast Cell Proliferative Disorders: A 17 Year Experience in a Single Center.. <i>Blood</i> , 2004, 104, 4741-4741.	1.4	0
719	Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders.. <i>Blood</i> , 2004, 104, 4754-4754.	1.4	0
720	Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.. <i>Blood</i> , 2005, 106, 1987-1987.	1.4	0

#	ARTICLE	IF	CITATIONS
721	Prognostic Significance of Serial Determinations of LDH Levels in Primary (De Novo) Myelodysplastic Syndromes.. Blood, 2006, 108, 4828-4828.	1.4	0
722	Prognostic Factors Predicting Survival in De Novo AML Patients Requiring Intensive Care.. Blood, 2007, 110, 2860-2860.	1.4	0
723	The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.. Blood, 2007, 110, 3554-3554.	1.4	0
724	Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.. Blood, 2007, 110, 4556-4556.	1.4	0
725	Spectrum, Function, and Value of Targets Expressed in Neoplastic Mast Cells. , 2009, , 107-125.		0
726	Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax®) on Growth and Viability of Canine and Human Neoplastic Mast Cells. Blood, 2008, 112, 861-861.	1.4	0
727	Revealing Six Phases of CML Stem Cell Development to Explain Clinical Phenomena Seen in TKI-Treated Patients.. Blood, 2009, 114, 4263-4263.	1.4	0
728	BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.. Blood, 2010, 116, 3382-3382.	1.4	0
729	Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy. Blood, 2011, 118, 2504-2504.	1.4	0
730	Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis.. Blood, 2012, 120, 2866-2866.	1.4	0
731	Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra. Blood, 2012, 120, 1760-1760.	1.4	0
732	Clofarabine/Cyclophosphamide (ClofCy) for Debulking refractory Acute Leukemias Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 4504-4504.	1.4	0
733	Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML. Blood, 2014, 124, 4526-4526.	1.4	0
734	Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event. Blood, 2014, 124, 3216-3216.	1.4	0
735	Gene Expression and Mutation Analysis (GEMA) â€“Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK â€“Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells. Blood, 2014, 124, 480-480.	1.4	0
736	Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56bright NK Cells in Acute Myeloid Leukemia. Blood, 2014, 124, 1422-1422.	1.4	0
737	Paul Ehrlich (1854-1915) and the Birth of Molecular Medicine. , 2015, 12, .		0
738	Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML. Blood, 2015, 126, 1571-1571.	1.4	0

#	ARTICLE	IF	CITATIONS
739	Mastozytosen. , 2019, , 95-113.		0
740	History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis. , 2020, , 287-299.		0
741	Isolation and Culture of Mast Cells and Basophils. , 2002, , 241-257.		0
742	Impact of gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. American Journal of Cancer Research, 2021, 11, 955-967.	1.4	0
743	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. Blood, 2020, 136, 40-41.	1.4	0
744	Phenotyping of Disease-Initiating CD34+/CD38 ⁺ Stem Cells in BCR-ABL1 ⁺ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens. Blood, 2020, 136, 53-53.	1.4	0
745	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematological Oncology, 2022, 40, 491-504.	1.7	0
746	Reply to "Need to define a subgroup of patients with idiopathic mast cell activation syndrome". Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1128.	3.8	0
747	PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.. American Journal of Cancer Research, 2021, 11, 6042-6059.	1.4	0
748	CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. Cancers, 2022, 14, 3070.	3.7	0